Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.67 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.67 |
| ▸ | EEF2K | O00418 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677738 | 1.00 | PTGS2 (0.67) | PTGS2PTGS1ALOX5EEF2KSRC | |
| SCHEMBL677737 | 1.00 | PTGS2 (0.67) | PTGS2PTGS1ALOX5EEF2KSRC | |
| SCHEMBL14478505 | 0.90 | PTGS2 (0.67) | PTGS2PTGS1ALOX5EEF2KSRC | |
| SCHEMBL8961980 | 0.86 | PTGS2 (0.68) | PTGS2PTGS1ALOX5EEF2KSRC | |
| SCHEMBL8961971 | 0.86 | PTGS2 (0.68) | PTGS2PTGS1ALOX5EEF2KSRC | |
| SCHEMBL8961993 | 0.85 | PTGS2 (0.60) | PTGS2PTGS1ALOX5EEF2KSRC | |
| SCHEMBL8962140 | 0.85 | PTGS2 (0.60) | PTGS2PTGS1ALOX5EEF2KSRC | |
| SCHEMBL8962142 | 0.85 | PTGS2 (0.60) | PTGS2PTGS1ALOX5EEF2KSRC | |
| Hydrochloric Acid SCHEMBL7702116 | 0.84 | PTGS2 (0.59) | PTGS2PTGS1ALOX5EEF2KSRC | |
| Hydrochloric Acid SCHEMBL7702117 | 0.84 | PTGS2 (0.59) | PTGS2PTGS1ALOX5EEF2KSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0449216-B1 | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents | WARNER LAMBERT CO (US) | 1996-02-07 | — | — | EP | claimed |
| US-5143928-A | Inhibitors of cyclooxygenase and lipoxygenase | WARNER-LAMBERT COMPANY (US) | 1992-09-01 | — | — | US | claimed |
| EP-0449216-A1 | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1991-10-02 | — | — | EP | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| WO-2014176460-A1 | METHODS OF TREATING BEHAVIORIAL AND/OR MENTAL DISORDERS | CHAU DAVID T (US) | 2014-10-30 | — | — | WO | disclosed |
| US-8486922-B2 | Composition | CHEN CHIEN-HUNG (TW) | 2013-07-16 | — | — | US | disclosed |
| US-20130005718-A1 | COMPOSITIONS AND METHODS OF TREATING CHRONIC PAIN BY ADMINISTERING PROPOFOL DERIVATIVES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2013-01-03 | — | — | US | disclosed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110281829-A1 | NOVEL COMPOSITION | IPINTL, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2011019747-A1 | COMPOSITIONS AND METHODS OF TREATING CHRONIC PAIN BY ADMINISTERING PROPOFOL DERIVATIVES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | PTGS2 99/4885PTGS1 76/4885ALOX5 25/4885 |
| US-20130005718-A1 | COMPOSITIONS AND METHODS OF TREATING CHRONIC PAIN BY ADMINISTERING PROPOFOL DERIVATIVES | HCN3, HCN1, HCN2 | PTGS2 228/4885PTGS1 227/4885ALOX5 426/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | PTGS2 99/4885PTGS1 76/4885ALOX5 25/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | PTGS2 1253/4885PTGS1 593/4885ALOX5 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.